Paper36644397
ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe.
Heyza JR and 17 others. NAR Cancer, 2023. Cited by 13 papers, by iCite.
Cite this record
ConductScience Library. ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe. Papers, record 36644397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36644397
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA229535 | NCI NIH HHS | United States | R01CA229535 | PubMed and NIH | NIH RePORTER |
| R01 CA141769 | NCI NIH HHS | United States | R01CA141769 | PubMed and NIH | NIH RePORTER |
| R50 CA251068 | NCI NIH HHS | United States | R50CA251068 | PubMed | NIH RePORTER |
| R01 CA180710 | NCI NIH HHS | United States | R01CA180710 | PubMed | NIH RePORTER |
| T32 CA009531 | NCI NIH HHS | United States | T32CA009531 | PubMed and NIH | NIH RePORTER |
| P30 CA022453 | NCI NIH HHS | United States | P30CA022453 | PubMed and NIH | NIH RePORTER |
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21716293 | Diverse system stresses: common mechanisms of chromosome fragmentation. | Cell Death Dis | 2011 | https://conductscience.org/library/papers/21716293 | PubMed |
| 2 | 12003190 | Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing mice. | Invest New Drugs | 2002 | https://conductscience.org/library/papers/12003190 | PubMed |
| 3 | 31506018 | A consensus set of genetic vulnerabilities to ATR inhibition. | Open Biol | 2019 | https://conductscience.org/library/papers/31506018 | PubMed |
| 4 | 21750204 | Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. | Clin Cancer Res | 2011 | https://conductscience.org/library/papers/21750204 | PubMed |
| 5 | 12114432 | Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. | Clin Cancer Res | 2002 | https://conductscience.org/library/papers/12114432 | PubMed |
| 6 | 28759889 | Mitotic progression following DNA damage enables pattern recognition within micronuclei. | Nature | 2017 | https://conductscience.org/library/papers/28759889 | PubMed |
| 7 | 27650543 | Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells. | Oncotarget | 2016 | https://conductscience.org/library/papers/27650543 | PubMed |
| 8 | 31529615 | Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells. | Mol Oncol | 2019 | https://conductscience.org/library/papers/31529615 | PubMed |
| 9 | 29252124 | Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29252124 | PubMed |
| 10 | 11481475 | ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. | Proc Natl Acad Sci U S A | 2001 | https://conductscience.org/library/papers/11481475 | PubMed |
| 11 | 21963239 | BRCA1 is required for postreplication repair after UV-induced DNA damage. | Mol Cell | 2011 | https://conductscience.org/library/papers/21963239 | PubMed |
| 12 | 9440758 | ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. | J Clin Oncol | 1998 | https://conductscience.org/library/papers/9440758 | PubMed |
| 13 | 35251993 | In Vivo Targeting Replication Protein A for Cancer Therapy. | Front Oncol | 2022 | https://conductscience.org/library/papers/35251993 | PubMed |
| 14 | 27893326 | Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). | J Clin Oncol | 2017 | https://conductscience.org/library/papers/27893326 | PubMed |
| 15 | 2393858 | Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systems. | Cancer Res | 1990 | https://conductscience.org/library/papers/2393858 | PubMed |
| 16 | 27997828 | A Mechanism for Controlled Breakage of Under-replicated Chromosomes during Mitosis. | Dev Cell | 2016 | https://conductscience.org/library/papers/27997828 | PubMed |
| 17 | 30139873 | An intrinsic S/G2 checkpoint enforced by ATR. | Science | 2018 | https://conductscience.org/library/papers/30139873 | PubMed |
| 18 | 30538112 | Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30538112 | PubMed |
| 19 | 24267891 | ATR prohibits replication catastrophe by preventing global exhaustion of RPA. | Cell | 2013 | https://conductscience.org/library/papers/24267891 | PubMed |
| 20 | 25965342 | A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. | PLoS One | 2015 | https://conductscience.org/library/papers/25965342 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42773173 | Replication stress in cancer: origins, consequences and therapeutic opportunities. | Nat Rev Cancer | 2026 | https://conductscience.org/library/papers/42773173 | PubMed |
| 42755018 | PD-L1 in Ovarian Cancer: Immune Evasion, Tumor-Intrinsic Signaling, and Chemoresistance. | Cancer Med | 2026 | https://conductscience.org/library/papers/42755018 | PubMed |
| 42049240 | Replication protein A protects lagging strand gaps, restricting PARP inhibitor-induced synthetic lethality in BRCA1-deficient tumors. | Nucleic Acids Res | 2026 | https://conductscience.org/library/papers/42049240 | PubMed |
| 41973002 | ATR and PKMYT1 Inhibition Resensitizes a Subset of TNBC Patient-Derived Models to Carboplatin, Inducing Mitotic Catastrophe. | Cancer Res Commun | 2026 | https://conductscience.org/library/papers/41973002 | PubMed |
| 41166929 | Drug-tolerant persister cells in head and neck squamous cell carcinoma: Molecular mechanisms and therapeutic opportunities. | Transl Oncol | 2026 | https://conductscience.org/library/papers/41166929 | PubMed |
| 38630271 | When DNA-damage responses meet innate and adaptive immunity. | Cell Mol Life Sci | 2024 | https://conductscience.org/library/papers/38630271 | PubMed |
| 38466804 | The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs. | Mol Cancer Ther | 2024 | https://conductscience.org/library/papers/38466804 | PubMed |
| 37633920 | The DDUP protein encoded by the DNA damage-induced CTBP1-DT lncRNA confers cisplatin resistance in ovarian cancer. | Cell Death Dis | 2023 | https://conductscience.org/library/papers/37633920 | PubMed |
Genes25
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36644397
GET https://conductscience.org/api/papers/v1/36644397/references?page=2